Background stories of how others approached and experienced their European Horizon funding trajectory.
Published on | 2 years ago
Programmes Digital, Industry & Space SPACEThe ROOT project obtained funding under Horizon 2020 topic ‘EGNSS applications fostering societal resilience and protecting the environment’. The project, which ran from November 2020 to July 2022, aimed to demonstrate the benefit of Galileo OSNMA signal to increase the robustness of critical telecom infrastructures.
The Flanders-based company Septentrio contributed substantially to completing this objective together with the other ROOT partners. The results of the project partially close a gap in the security of telecommunication networks dependent on satellite-derived time, with indirect benefits in curbing illegal attempts to disrupt network services.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.